Vernalis PLC Regulatory News (VER)

12 Nov 2007 15:13

Vernalis PLC12 November 2007 12 November 2007 VERNALIS TO PRESENT AT PIPER JAFFRAY 19TH ANNUAL HEALTHCARE CONFERENCE Vernalis plc (LSE: VER) today announced that Mr. Simon Sturge, Chief ExecutiveOfficer, and Mr. Tony Weir, Chief Financial Officer, will participate in ThePiper Jaffray 19th Annual Healthcare Conference in New York. Mr. Sturge isscheduled to present an overview of the Company's business activities andproduct pipeline, as well as, meet with investors. The conference will be held 27-29 November, 2007 at The Pierre Hotel in NewYork. Vernalis is scheduled to present at 4.00 pm Eastern time on 27 November.To listen to the audio webcast of the presentation, please visit: http://www.piperjaffray.com/conferences. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial Officer Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroyAlex Tweed Lazar Partners LtdGregory Gin +1 212-867-1762 Notes to Editors About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has has established a US commercialoperation to promote Apokyn (R) and co-promote Frova (R) alongside its NorthAmerican licensing partner, Endo Pharmaceuticals. The company has seven productsin clinical development focused on neurology and central nervous systemdisorders and collaborations with leading, global pharmaceutical companiesincluding Novartis, Biogen Idec and Chiesi. For further information aboutVernalis, please visit www.vernalis.com. Product Indication Phase Phase Phase Registration Market Marketing I II III Rights Apokyn(R) Parkinson's X North America Disease Frova(R) Migraine X US Co-promotion Endo (EU-royalties) Frova(R) Menstrual X US Migraine Co-promotion Prevention Endo (EU-royalties) V1512 Parkinson's X World Wide Disease (excl. Italy) V10153 Thrombotic X World Wide Disorders V3381 Neuropathic X World Wide Pain V2006 Parkinson's X US Disease Co-promotion Biogen Idec V24343 Obesity X World Wide Hsp90 Cancer X None - royalty (Novartis) Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products, the Company'sability to find partners for the development and commercialisation of itsproducts, as well as the Company's future capital raising activities.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the ability of theCompany to identify and agree beneficial terms with suitable partners for thecommercialisation and/or development of its products, as well as the achievementof expected synergies from such transactions, the acceptance of Frova(R) andApokyn(R) and other products by consumers and medical professionals, thesuccessful integration of completed mergers and acquisitions and achievement ofexpected synergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock Exchange